



瑞 阳 制 药 股 份 有 限 公 司
REYOUNG PHARMACEUTICAL CO., LTD.

Date: November 21, 2023

VIA ELECTRONIC SUBMISSION

Division of Dockets Management
Food and Drug Administration (HFA-305)
FDA's Division of Dockets Management
5630 Fishers Lane
Room 1061, HFA-305
Rockville, MD 20852

WITHDRAW OF SUITABILITY PETITION

Dear Sir or Madam:

We have submitted the petition suitability for requesting the Commissioner of the Food and Drug Administration ("FDA") to declare that the proposed drug product, posaconazole for delayed-release oral suspension, USP, 100 mg is suitable for consideration in an Abbreviated New Drug Application ("ANDA"). The assigned docket number FDA-2022-P-1833.

Now we submit the letter to withdraw our petition which assigned docket number is FDA-2022-P-1833.

During the course of the review of this application, if there are any questions or comments, please do not hesitate to contact us via telephone at +86-13301630770 or e-mail: wangying@hqdds.com or shao.wei@reyoung.com.

Respectfully submitted,

Huang Jingshan

Vice President

Reyoung Pharmaceutical Co., Ltd.

Add.: No.1, Ruiyang Road, Yiyuan County, Shandong Province, China.
Tel: 86 533 3223935 Fax: 86 533 3224277
E-mail: shao.wei@reyoung.com Http://www.reyoung.com